Doctor Who Sold $12 Billion Drug Firm Eyes Biotech Property

Doctor Who Sold $12 Billion Drug Firm Eyes Biotech Property
Doctor Who Sold $12 Billion Drug Firm Eyes Biotech Property  

(Bloomberg) -- A deal-making cancer doctor who sold his pharmaceutical company for almost $12 billion is launching a real estate venture to bolster the growth of the biotechnology industry.

Arie Belldegrun's family office, Bellco Capital, has entered into a joint venture with New York-based real estate developer Tishman Speyer to start Breakthrough Properties, the companies said Tuesday in a statement. The venture said it bought its first property, a 1-acre (0.4 hectare) development site in Boston's Seaport District, for $80 million, and is exploring other acquisitions in the area as well as in San Francisco.

"This came out of necessity," Belldegrun said in a telephone interview. "I realized that there's a significant need for an ecosystem in life sciences where scientists can work and interact."

Belldegrun, 69, is a UCLA-based cancer researcher and surgeon who's emerged as a serial entrepreneur and venture capitalist. He sold Kite Pharma, which develops genetically engineered cancer treatments, in 2017 to Gilead Sciences Inc. for $11.9 billion and since then has helped launch Vida Ventures to start more pharma companies.

Boston Site

Breakthrough Properties will provide various business development services to help tenants grow, Belldegrun said. Vida Ventures, his venture capital arm, may also take stakes in the biotech firms. The Seaport District site comes with 250,000 square feet (23,200 square meters) of development rights and is expected to be finished by 2021, according to the statement.

Breakthrough's chief executive officer is Belldegrun's son Dan, who worked for Tishman Speyer for several years. Belldegrun's wife, Rebecka, who is also a doctor, manages Bellco Capital, the family office formed in 2003.

The venture -- a foray into life-sciences development for Tishman Speyer -- will face competition from companies such as Alexandria Real Estate Equities Inc., which built its business around catering to biotech tenants. About a quarter of Alexandria's 250 properties are in the Boston area, while the remainder are spread across U.S. cities including San Francisco, New York and San Diego.

Breakthrough has its sights set on some of those cities and ultimately has plans to expand globally, according to Tishman Speyer CEO Rob Speyer.

"The last thing a life-sciences company should be worrying about is real estate, and we can take that concern off the table for them," Speyer said in an interview. "We're going to focus on strategic cities that have biotech companies, leading universities and quality housing options."

Tishman Speyer, whose properties include New York's Rockefeller Center, last year sold a 13-story building in Boston's burgeoning Seaport District for $450 million, setting a record for an office transaction in the city.

(Adds potential for competition with Alexandria in seventh paragraph.)

To contact the reporters on this story: Michael McDonald in Boston at;Lily Katz in New York at

To contact the editors responsible for this story: Alan Mirabella at, Josh Friedman, Christine Maurus

For more articles like this, please visit us at

©2019 Bloomberg L.P.


More Related News

Fukushima Radiation Becomes Latest Japan-South Korea Sore Point
Fukushima Radiation Becomes Latest Japan-South Korea Sore Point

(Bloomberg) -- Radiation from the crippled Fukushima nuclear plant is becoming the latest source of tension between Japan and South Korea, potentially undercutting Tokyo's effort to promote the 2020 Olympics.In recent days, South Korean officials have summoned a Japanese diplomat to express concern about a planned release of treated radioactive water into the ocean by Tepco, the plant's owner. They're also pushing for independent radiation checks at Olympic venues and proposing a separate cafeteria for their athletes, citing concerns about contaminated food.The radiation dispute is threatening to prolong tensions between the two U.S. allies, who have spent much of the summer trading...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


Top News: Economy

Hit "Like"
Don't miss any important news
Thanks, you don't need to show me this anymore.